Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for SELLAS Life Sciences Group, Inc. (SLS : NSDQ)

• Company Description    SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $3.77 Daily Weekly Monthly 20 Day Moving Average: 8,464,850 shares Shares Outstanding: 142.44 (millions) Market Capitalization: $537.01 (millions) Beta: 2.26 52 Week High: $4.45 52 Week Low: $0.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 116.67% 117.03% 12 Week 98.94% 95.74% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 TIMES SQUARE SUITE 2503 - NEW YORK,NY 10036 USA ph: 646-200-5278 fax: 441-400-2875 sellas@lifesciadvisors.com http://www.sellaslifesciences.com

• General Corporate Information    Officers Angelos M. Stergiou - Chief Executive Officer;President John Varian - Chair of the Board of Directors John T. Burns - Senior Vice President; Chief Financial Officer David Scheinberg - Director Robert Van Nostrand - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81642T209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 142.44 Most Recent Split Date: 11.00 (0.02:1) Beta: 2.26 Market Capitalization: $537.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -95.20 06/30/25 - -132.51 ROA 12/31/25 - - 09/30/25 - -75.06 06/30/25 - -92.79 Current Ratio 12/31/25 - - 09/30/25 - 8.28 06/30/25 - 4.91 Quick Ratio 12/31/25 - - 09/30/25 - 8.28 06/30/25 - 4.91 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 0.36 06/30/25 - 0.26 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©